Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • unsolvedquestions
    Junior Member
    • Mar 2018
    • 1

    Urgent help needed

    Hi everyone. I am sorry for asking a question that may sound very trivial to many of you but I am new to this field and do not have a bioinformatics background. Actually WES was done for 4 tumor samples which showed a mapping rate of 70-85% after alignment with BWA. Now I am reading everywhere that Mapping rate must be >90% but I am getting a low mapping rate. I want to know what can be the possible reasons for getting such low mapping rate and can we proceed with variant calling with such low mapping rate. Will the variant calling data be acceptable?

    Thank you
  • GenoMax
    Senior Member
    • Feb 2008
    • 7142

    #2
    While your mapping rate is lower (you could take a selection of reads that don't map and blast them at NCBI to figure out what they are) you should be able to proceed with further analysis. Assuming you have enough coverage to do SNP calling (>15-20x).

    Comment

    • gringer
      David Eccles (gringer)
      • May 2011
      • 845

      #3
      I'd recommend doing an analysis on the unmapped reads to make sure that they are not hitting something other than your intended target. With a tumour sample it's unlikely to be a contamination issue, but just in case, you could feed the unmapped reads through Centrifuge or OneCodex just to be sure of that.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM
      • SEQadmin2
        Cancer Drug Resistance: The Lingering Barrier to Rising Survival
        by SEQadmin2



        Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

        There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
        07-08-2026, 05:17 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, 07-20-2026, 11:10 AM
      0 responses
      21 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-13-2026, 10:26 AM
      0 responses
      33 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-09-2026, 10:04 AM
      0 responses
      44 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-08-2026, 10:08 AM
      0 responses
      30 views
      0 reactions
      Last Post SEQadmin2  
      Working...